Talbot Financial LLC Boosts Stock Position in Eli Lilly and Company (NYSE:LLY)

Talbot Financial LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 4.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 17,077 shares of the company’s stock after purchasing an additional 789 shares during the quarter. Eli Lilly and Company comprises about 1.8% of Talbot Financial LLC’s holdings, making the stock its 20th largest position. Talbot Financial LLC’s holdings in Eli Lilly and Company were worth $15,129,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Visionary Wealth Advisors boosted its holdings in Eli Lilly and Company by 2.7% in the 4th quarter. Visionary Wealth Advisors now owns 1,872 shares of the company’s stock valued at $1,091,000 after purchasing an additional 49 shares during the period. Hancock Whitney Corp boosted its stake in Eli Lilly and Company by 21.0% during the fourth quarter. Hancock Whitney Corp now owns 35,612 shares of the company’s stock valued at $20,759,000 after buying an additional 6,174 shares during the period. Northwest Wealth Management LLC grew its position in Eli Lilly and Company by 30.8% during the fourth quarter. Northwest Wealth Management LLC now owns 895 shares of the company’s stock worth $522,000 after buying an additional 211 shares in the last quarter. Vista Investment Management bought a new position in Eli Lilly and Company in the 4th quarter worth about $201,000. Finally, Ethic Inc. raised its holdings in shares of Eli Lilly and Company by 3.2% in the 4th quarter. Ethic Inc. now owns 62,512 shares of the company’s stock valued at $36,440,000 after acquiring an additional 1,940 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

LLY opened at $913.72 on Wednesday. The stock has a fifty day simple moving average of $901.94 and a two-hundred day simple moving average of $849.30. The company has a market cap of $868.40 billion, a price-to-earnings ratio of 134.57, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Research analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on LLY shares. Barclays upped their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Truist Financial reaffirmed a “buy” rating and set a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Wells Fargo & Company increased their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Citigroup assumed coverage on Eli Lilly and Company in a research note on Friday, September 13th. They set a “buy” rating and a $1,060.00 price target for the company. Finally, Berenberg Bank increased their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.